154650-16-5

Usage

Uses

Used in Organic Synthesis:
2-BROMO-6-FLUORO-3-METHYLBENZALDEHYDE is used as a building block in organic synthesis for creating more complex organic compounds through various chemical reactions. Its unique structure and reactivity contribute to the formation of diverse molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-BROMO-6-FLUORO-3-METHYLBENZALDEHYDE is used as an intermediate in the production of various drugs. Its distinctive chemical properties allow for the development of new pharmaceutical compounds with specific therapeutic effects.
Used in Agrochemical Industry:
2-BROMO-6-FLUORO-3-METHYLBENZALDEHYDE is also utilized as an intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and structural features enable the creation of effective compounds for agricultural applications, helping to protect crops and enhance yield.

Upstream product

• 1422-53-3 2-bromo-4-fluorotoluene 
• 109-94-4 formic acid ethyl ester 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1056214-74-4 2-bromo-6-methoxy-3-methylbenzaldehyde 
• 1404115-09-8 C₂₂H₂₀F₄N₄O₃ 
• 1404115-08-7 C₂₃H₂₂F₄N₄O₃ 
• 1404115-67-8 C₁₄H₁₆FN₃O 
• 1256483-11-0 C₉H₇BrFN 

Relevant academic research and scientific papers

Preparation method of 4-bromo-5-methyl-1H-indazole

The invention discloses a preparation method of 4-bromo-5-methyl-1H-indazole, wherein the preparation method comprises the specific steps: (1) reacting a compound (II) in the presence of lithium diisopropylamide to generate a lithium reagent, and reacting

Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors

A series of exiguamine A analogues were designed and synthesized via 15 steps. Their inhibitory activities against IDO1 were tested and the structure-activity relationships were studied. Most compounds exhibited potent IDO1 inhibitory activities with IC50 values at the level of 10?7–10?8 M. Compound 21f was the most potent IDO1 inhibitor with an IC50 value of 65.3 nM, which was comparable with the positive control drug epacadostat (IC50 = 46 nM). Moreover, compound 21f showed higher selectivity for IDO1 over tryptophan 2,3-dioxygenase (TDO) and no cytotoxicity at its effective concentration, rending it justifiable for further optimization and evaluation.

INHIBITING HUMAN INTEGRIN α4β7

Disclosed are small molecule antagonists of human α4β7 integrin, and methods of using them to treat a number of diseases and conditions.

QUINOXALINE DERIVATIVES

The present invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Dihydroisocoumarin derivative and preparation method and application thereof

The present invention discloses a dihydroisocoumarin derivative and preparation method and application thereof, the dihydroisocoumarin derivative having a structure as shown in formula (I) or (II). The method of preparing dihydroisocoumarin derivatives of

2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS

The present invention provides e.g. 2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-6-(lH-indazol-4-yl)-benzonitrile and e.g. 2-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-6-(1H-indazol-4-yl)- benzonitrile derivatives and related compounds of formula (I) as inhibitors of G12C mutant KRAS protein for treating tumor metastasis. The present description discloses exemplary compounds (e.g. pages 53 to 90; table 1; compounds I-1 to I-141), pharmacological data (e.g. page 125 to 128; table 2; example 1) and synthesis thereof (e.g. pages 129 to 143; examples 2 to 7). Exemplary compounds are e.g. 2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-6-(5-methyl-1H-indazol-4-yl)-4- morpholinobenzonitrile (example 2; compound I-1) and 6-(2- acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-3-methoxy-2-(5-methyl-1H- indazol-4-yl)-4-morpholinobenzonitrile (example 7; compound I-84).

COVALENT INHIBITORS OF KRAS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, R2a,

BORON-CONTAINING SMALL MOLECULES

Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.

(Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

(AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS

The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.